There are four possible results from the cervical screening process, all of which require different action to be taken. These are: Low risk (HPV not detected): This means that no high-risk (cancer causing) HPV was found on your cervix. The chance of developing cervical cell changes that would need treatment in the next five years are very low.
1. To accept p16 IHC as a standalone test only in populations with a high prevalence of HPV and defining a threshold (e.g., 50%, which would be associated with (1-specificity) = 5% in the best case scenario, according to the above formula for the prevalence of HPV-driven OPSCC, above which the expected rate of false positive p16IHC is99.7% of high risk HPV is attributable to developing cervical cancer. The discovery that high-risk HPV as a cause of virtually all cervical carcinoma has prompted international interest in the use of HPV DNA testing in cervical cancer screening programmes. High-risk HPV testing will be incorporated in cervical cancer screening from 2019.
A total of 5880 women with normal cytology and hr-HPV infection accepted colposcopic biopsy were enrolled in this study. 4332 women underwent HPV genotyping test and 1548 women were hr-HPV DNA positive by HC2 hr-HPV DNA test (Fig. 1). The median age was 39 years (26–81), and the average age was 39.29 ± 9.72 years. The HPV test and the Pap test can help prevent cervical cancer or find it early. The HPV test looks for the virus ( human papillomavirus) that can cause cell changes on the cervix. The Pap test (or Pap smear) looks for precancers, cell changes on the cervix that might become cervical cancer if they are not treated appropriately.The ASC-US/LSIL Triage Study (ALTS) is a clinical multicenter randomized study, sponsored by the National Cancer Institute, designed to compare three management options in ASC-US positive patients. The HPV-DNA test showed the most sensitivity and identified 96.3% (95% CI 91.6–98.8) of the women with CIN3+ [ 16 ].
QakkaXB.